Suppr超能文献

上尿路尿路上皮癌手术后的膀胱复发:危险因素与管理策略的当代综述

Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies.

作者信息

Mertens Laura S, Sharma Vidit, Matin Surena F, Boorjian Stephen A, Houston Thompson R, van Rhijn Bas W G, Masson-Lecomte Alexandra

机构信息

Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Department of Urology, Mayo Clinic, Rochester, MN, USA.

出版信息

Eur Urol Open Sci. 2023 Jan 28;49:60-66. doi: 10.1016/j.euros.2023.01.004. eCollection 2023 Mar.

Abstract

CONTEXT

Bladder recurrences have been reported in 22-47% of patients after surgery for upper urinary tract urothelial carcinoma (UTUC). This collaborative review focuses on risk factors for and treatment strategies to reduce bladder recurrences after upper tract surgery for UTUC.

OBJECTIVE

To review the current evidence on risk factors and treatment strategies for intravesical recurrence (IVR) after upper tract surgery for UTUC.

EVIDENCE ACQUISITION

This collaborative review is based on a literature search of PubMed/Medline, Embase, Cochrane Library, and currently available guidelines on UTUC. Relevant papers on bladder recurrence (etiology, risk factors, and management) after upper tract surgery were selected. Special attention has been paid to (1) the genetic background of bladder recurrences, (2) bladder recurrences after ureterorenoscopy (URS) with or without a biopsy, and (3) postoperative or adjuvant intravesical instillations. The literature search was performed in September 2022.

EVIDENCE SYNTHESIS

Recent evidence supports the hypothesis that bladder recurrences after upper tract surgery for UTUC are often clonally related. Clinicopathologic risk factors (patient, tumor, and treatment related) have been identified for bladder recurrences after UTUC diagnosis. Specifically, the use of diagnostic ureteroscopy before radical nephroureterectomy (RNU) is associated with an increased risk of bladder recurrences. Further, a recent retrospective study suggests that performing a biopsy during ureteroscopy may further worsen IVR (no URS: 15.0%; URS without biopsy: 18.4%; URS with biopsy: 21.9%). Meanwhile, a single postoperative instillation of intravesical chemotherapy has been shown to be associated with a reduced bladder recurrence risk after RNU compared with no instillation (hazard ratio 0.51, 95% confidence interval 0.32-0.82). Currently, there are no data on the value of a single postoperative intravesical instillation after ureteroscopy.

CONCLUSIONS

Although based on limited retrospective data, performing URS seems to be associated with a higher risk of bladder recurrences. Future studies are warranted to assess the influence of other surgical factors as well as the role of URS biopsy or immediate postoperative intravesical chemotherapy after URS for UTUC.

PATIENT SUMMARY

In this paper, we review recent findings on bladder recurrences after upper tract surgery for upper urinary tract urothelial carcinoma.

摘要

背景

据报道,上尿路尿路上皮癌(UTUC)手术后22%-47%的患者会出现膀胱复发。本协作综述聚焦于UTUC上尿路手术后膀胱复发的危险因素及降低复发的治疗策略。

目的

综述UTUC上尿路手术后膀胱内复发(IVR)的危险因素及治疗策略的现有证据。

证据收集

本协作综述基于对PubMed/Medline、Embase、Cochrane图书馆的文献检索以及当前可用的UTUC指南。选取了关于上尿路手术后膀胱复发(病因、危险因素及管理)的相关论文。特别关注了以下方面:(1)膀胱复发的遗传背景;(2)输尿管肾镜检查(URS)无论有无活检后的膀胱复发;(3)术后或辅助膀胱内灌注。文献检索于2022年9月进行。

证据综合

近期证据支持以下假说,即UTUC上尿路手术后的膀胱复发通常具有克隆相关性。已确定UTUC诊断后膀胱复发的临床病理危险因素(与患者、肿瘤及治疗相关)。具体而言,根治性肾输尿管切除术(RNU)前进行诊断性输尿管镜检查与膀胱复发风险增加相关。此外,一项近期的回顾性研究表明,输尿管镜检查时进行活检可能会进一步加重IVR(未行URS:15.0%;未活检的URS:18.4%;活检的URS:21.9%)。同时,与未灌注相比,RNU术后单次膀胱内化疗灌注已显示与降低膀胱复发风险相关(风险比0.51,95%置信区间0.32-0.82)。目前,尚无关于输尿管镜检查后单次术后膀胱内灌注价值的数据。

结论

尽管基于有限的回顾性数据,但进行URS似乎与较高的膀胱复发风险相关。未来有必要开展研究,以评估其他手术因素的影响以及URS活检或URS后即刻术后膀胱内化疗在UTUC中的作用。

患者总结

在本文中,我们综述了上尿路尿路上皮癌上尿路手术后膀胱复发的近期研究结果。

相似文献

1
Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies.
Eur Urol Open Sci. 2023 Jan 28;49:60-66. doi: 10.1016/j.euros.2023.01.004. eCollection 2023 Mar.
8
Correlation Between the Timing of Diagnostic Ureteroscopy and Intravesical Recurrence in Upper Tract Urothelial Cancer.
Clin Genitourin Cancer. 2016 Feb;14(1):e37-41. doi: 10.1016/j.clgc.2015.07.008. Epub 2015 Aug 6.

引用本文的文献

5
Advances in chemoablation in upper tract urothelial carcinoma: overview of indications and treatment patterns.
Transl Androl Urol. 2023 Sep 30;12(9):1449-1455. doi: 10.21037/tau-23-69. Epub 2023 Aug 1.

本文引用的文献

3
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041.
5
Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma.
Clin Genitourin Cancer. 2022 Feb;20(1):95.e1-95.e6. doi: 10.1016/j.clgc.2021.10.002. Epub 2021 Oct 10.
8
Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
J Urol. 2021 Sep;206(3):548-557. doi: 10.1097/JU.0000000000001788. Epub 2021 Apr 21.
9
Cancer Statistics, 2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
10
Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study.
World J Urol. 2021 Sep;39(9):3385-3391. doi: 10.1007/s00345-020-03576-3. Epub 2021 Jan 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验